Daniel Kenny

Daniel Kenny serves as Chief Executive Officer at OncoSil Medical. OncoSil Medical operates in the medical devices sector with approximately 27.0 employees. The company is headquartered in Sydney, New South Wales.

Industry & Role Insights

• • MessageCEO tracks 1,888 executives in the medical devices sector.
• • 3,176 executive contacts are available in New South Wales.
• • Our database includes 201,469 c suite-level executives.

Cloudflare DNS Outlook Google Cloud Hosting Google Maps Nginx Google Tag Manager Linkedin Marketing Solutions Mobile Friendly Vimeo WordPress.org reCAPTCHA Cedexis Radar Google Font API Adobe Media Optimizer Remote

interventional oncology medical equipment manufacturing oncosil brachytherapy phosphorous-32 pancreatic cancer radiation therapy intratumoural implantation chemotherapy endoscopic ultrasound targeted radiation unresectable cancer tumour treatment microparticles cancerous tissue clinical trials surgery eligibility tumour shrinkage safety & efficacy cancer cell dna damage medical device patient outcomes healthcare professionals fda approval ce marking pharmaceutical industry clinical research radiation safety patient monitoring treatment protocol treatment centers evidence-based treatment regulatory affairs clinical studies treatment guidelines microsurgery medical technology investor relations market access clinical development oncology advancements patient care radiotherapy immunotherapy chemotherapy cycles tumour reduction risk management medical devices hospital & health care health care health wellness & fitness

YM

Yahia Megahed CEO at 360Imaging

HA

Hugo Azevedo Chief Technology Officer at 3B Scientific

MP

Marie-Laure Pochon CEO & President at 3DISC

KD

Khanh Duy Co-CEO at 3D-Side

K

Khanh Co-CEO at 3D-Side

Outreach Guidance — medical devices Sector

Executives like Daniel Kenny in the medical devices sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at OncoSil Medical.

Daniel Kenny's Position in the MessageCEO Database

• •Daniel Kenny is 1 of 1 verified executive contact we track at OncoSil Medical.
• •1,787 verified executive contacts in medical devices are in the MessageCEO database.
• •3,103 verified executive contacts in New South Wales are in the database.
• •35 verified contacts work at medical devices companies in the 27.0 employee range (same size as OncoSil Medical).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach Daniel Kenny directly?

Daniel Kenny's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Executive Officer at OncoSil Medical. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Daniel Kenny work for?

Daniel Kenny is Chief Executive Officer at OncoSil Medical, a company in the medical devices sector with 27.0 employees. The company is based in Sydney, New South Wales.

Can I pitch or sell to Daniel Kenny?

As Chief Executive Officer at OncoSil Medical, Daniel Kenny is a key decision-maker in the medical devices sector. MessageCEO Pro gives you verified email to reach Daniel Kenny directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Daniel Kenny in?

Daniel Kenny works in the medical devices industry as Chief Executive Officer at OncoSil Medical. MessageCEO provides verified contact information for executives across all major industries.

Is Daniel Kenny's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Daniel Kenny's profile is kept up-to-date with the latest available information.

Last updated: July 23, 2026